Today, Crystal Research Associates has issued a 76-page Executive Informational Overview® (EIO) on California biopharmaceutical company Amarantus BioScience Holdings, Inc. (AMBS-OTC). The EIO details the Company's pipeline development, business model, growth strategies, market opportunities, potential milestones, competitive landscape, financial position, business risks, and more. It is available for download on our website here. A summary of Amarantus' 12 competitive advantages in its target diagnostics and therapeutics fields is available here: Amarantus' Key Points.
Introduction to Amarantus
Amarantus is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products to treat diseases related to neurodegeneration and abnormal apoptosis (cell death). The company’s initial focus is on Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its pipeline includes an exclusive worldwide license to the Lymphocyte Proliferation Test (the LymPro Test®), a diagnostic blood platform for AD that could be the first of its kind to reach the market. In PD, the company aims to enable earlier and better diagnoses using its blood-based NuroPro test.
As well, Amarantus holds a license to Eltoprazine, a Phase 2b-ready therapeutic to treat the debilitating side effects of existing Parkinson’s treatments, known as Levodopa-Induced Dyskinesia (PD-LID). Eltoprazine’s clinical data to date may also position it to treat Adult Attention Deficit Hyperactivity Disorder (Adult ADHD). Amarantus is further building a global intellectual property position around Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a therapeutic protein with potential in orphan diseases that, today, lead to incurable blindness in patients, in addition to potential for other indications. The company is located at Janssen Labs @QB3, a subsidiary of Johnson & Johnson that acts as an incubator for companies of interest to J&J’s core positions.
Highlights from the Executive Informational Overview
Alzheimer’s disease (AD) is a major field for healthcare research, with nearly 130 AD trials ongoing or recently completed in the U.S. alone. This is likely due to the disease’s considerable unmet needs: it is the only one of the top 10 causes of deaths in the U.S. that cannot yet be prevented, cured, or slowed.
Amarantus aims to launch the LymPro Test® for AD in the U.S. in the fourth quarter of 2014 as a Laboratory Developed Test (LDT). By distinguishing between an AD patient and a patient with another form of dementia, the company’s assay could become a valuable tool used by clinical researchers. AD trials have a history of patient recruitment errors stemming from inaccurate dementia diagnoses.
During 2014, the company plans to commence a Phase 2b trial of Eltoprazine for PD-LID patients, and is preparing to file an Orphan Drug Designation and subsequent Investigational New Drug (IND) application with the FDA for MANF.
Amarantus has recently strengthened its management team, hiring individuals who can position the company’s products within the competitive landscape and help build a global biotechnology holding company to bring assets through the development process.
The company is also a Founding Member of the Coalition for Concussion Treatment (#C4CT), a program initiated in collaboration with Brewer Sports International to raise awareness of treatments in development for concussions and nervous system disorders.
At June 30, 2014, Amarantus had cash and cash equivalents of approximately $1.4 million, as well as access to an additional $19.6 million of equity capital under a financing facility.